India Pharma 2026, Triggering a Structural Rerating in Pharma Stocks

India Pharma 2026, held on April 13–14, 2026 in New Delhi, highlights India’s shift from a volume-driven generics hub to an innovation-led pharma powerhouse. India remains the 3rd largest globally by volume, supplies 60% of vaccines, and exported US$ 30.4 billion (₹2.5+ lakh crore) in FY25, growing 9.4% YoY, with the sector expected to expand 7–9% in FY26 led by strong domestic demand and Europe growth, despite moderate 3–5% US growth. The focus is now on R&D, biosimilars, specialty drugs, and CRDMO, supported by government push and rising global outsourcing. From a market perspective, this creates a long-term rerating opportunity. Key beneficiaries include

, !***** , , and (innovation + global play), along with !Divi’s Labs and (API & CRDMO outsourcing theme). The shift clearly signals that future alpha in pharma will be driven by innovation, not just scale. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.